PC
KYMR icon

Pier Capital’s Kymera Therapeutics KYMR Stock Holding History

Pier Capital’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.94M Buy
+16,948
New +$1.46M 0.26% 98

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Pier Capital's KYMR Position: Q2 2026 in Review

Pier Capital opened a new position in Kymera Therapeutics (KYMR) in Q2 2026: 16,948 shares worth $1.94M. The stake represents 0.26% of the portfolio and ranks #98 among its holdings.

275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Pier Capital held 16,948 shares of Kymera Therapeutics worth $1.94M as of Q2 2026.
  • Kymera Therapeutics was a new Pier Capital position in Q2 2026.
  • Kymera Therapeutics made up 0.26% of Pier Capital's portfolio in Q2 2026, its #98 holding.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Pier Capital's 13F filing for Q2 2026, filed 5 Aug 2026.